MINI FUTURE ZERTIFIKAT LONG - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 03:37:17 2024-07-16 pm EDT | ||
| 28.34 EUR | -1.39% |
|
| Current month | +3.77% | ||
| 1 month | +0.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 28.34 | -1.39% |
| 24-07-15 | 28.74 | +1.20% |
| 24-07-12 | 28.4 | -1.05% |
| 24-07-11 | 28.7 | +0.24% |
| 24-07-10 | 28.63 | +1.06% |
Real-time BOERSE MUENCHEN
Last update July 16, 2024 at 03:37 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | HSBC |
| WKN | TR0Y8Y |
| ISIN | DE000TR0Y8Y3 |
| Date issued | 2017-10-16 |
| Strike | 180.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 28.92 € |
|---|---|
| Lowest since issue | 1.51 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
489
USD
Average target price
473.5
USD
Spread / Average Target
-3.17%
- Stock Market
- Certificates
- Certificat
